Keyphrases
Chemotherapy
100%
Prostate Carcinoma
100%
Hormone Refractory
42%
Cytotoxic Chemotherapy
28%
Quality of Life
14%
United States
14%
High Risk
14%
Drug Combination
14%
Recent Advances
14%
Initial Treatment
14%
Antitumor Activity
14%
Cancer Mortality
14%
Treatment Options
14%
New Drugs
14%
Randomized Trial
14%
Systemic Chemotherapy
14%
MEDLINE
14%
Prostate-specific Antigen
14%
Quality of Life Assessment
14%
Cancer Causes
14%
Etoposide
14%
Phase II Study
14%
Pain Level
14%
Vinblastine
14%
New Agents
14%
Paclitaxel
14%
Docetaxel
14%
Mitoxantrone
14%
Pain Score
14%
Patient Benefit
14%
Activity Quality
14%
Secondary Hormonal Therapy
14%
Estramustine
14%
Antiandrogen Withdrawal Syndrome
14%
Chemotherapy Combinations
14%
Androgen Ablation Therapy
14%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Prostate Carcinoma
100%
Malignant Neoplasm
28%
Cytotoxic Chemotherapy
28%
Combination Drug
14%
Androgen
14%
Prostate Specific Antigen
14%
Etoposide
14%
Antitumor Activity
14%
Vinblastine
14%
Docetaxel
14%
Paclitaxel
14%
Mitoxantrone
14%
Hormone Cancer Therapy
14%
Withdrawal Syndrome
14%
Antiandrogen
14%
Estramustine
14%
Medicine and Dentistry
Prostate Carcinoma
100%
Quality of Life
28%
Malignant Neoplasm
28%
Cytotoxic Chemotherapy
28%
Clinician
14%
Hormone Therapy
14%
Antineoplastic Activity
14%
Androgen
14%
Combination Drug
14%
Prostate Specific Antigen
14%
Ablation Therapy
14%
Etoposide
14%
Docetaxel
14%
Paclitaxel
14%
Vinblastine
14%
Withdrawal Syndrome
14%
Combination Chemotherapy
14%
Mitoxantrone
14%
Antiandrogen
14%
Estramustine
14%
Nursing and Health Professions
Prostate Carcinoma
100%
Malignant Neoplasm
28%
Quality of Life
28%
Clinician
14%
Hormonal Therapy
14%
Prostate Specific Antigen
14%
Androgen
14%
Paclitaxel
14%
Ablation Therapy
14%
Vinblastine
14%
Combination Drug
14%
Antiandrogen
14%
Etoposide
14%
Docetaxel
14%
Withdrawal Syndrome
14%
Estramustine
14%
Combination Chemotherapy
14%
Antineoplastic Activity
14%
Mitoxantrone
14%